Leitat, in collaboration with the Institute for High Energy Physics (IFAE), has been awarded a €100,000 grant by the ATTRACT Project to develop a system that will enable safe, personalized, and robust cancer diagnosis and treatment. The system, named PHIL (Photonic System for Liquid Biopsy), will have the capability to isolate and analyze plasma tumor DNA (ptDNA) from blood samples in a non-invasive manner.
The project was officially launched on the 21st of May at CERN and was presented by Ruta Grinyte to the ATTRACT consortium, which is funding this initiative.
Over the next 12 months, Leitat and IFAE will design and build the PHIL system using primarily commercial solutions. They will commission the setup and determine the lowest target DNA levels that can be detected. The collaboration between IFAE, with its long-term expertise in detector development and integration, and Leitat, with its strong knowledge in medical research, creates a unique combination of expertise essential for the success of this project. The PHIL system has the potential for a wide range of applications in healthcare, addressing one of the key challenges for European society in the coming decade.
For more information about PHIL, please visit the official project page.
